For patients hospitalized with an acute illness, prescribing rivaroxaban for 45 days after discharge doesn’t significantly reduce the risk of venous thromboembolism (VTE) or VTE-related death, according to research presented at the European Society of Cardiology Congress and published online in the New England Journal of Medicine.